Company intelligence / Profile preview
Qnovia
Richmond, Virginia, United Statesqnovia.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Qnovia has received FDA IND clearance for its RespiRx™ Nicotine Inhaler (QN-01) and has completed positive first-in-human clinical trials. The company is advancing toward an MAA submission to the MHRA in 2026 for the UK market.
- Therapeutic areas
- PulmonologyPsychiatryNeurologyInfectious Diseases
- Modalities
- Inhaled drug delivery
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
University of Virginia
Beyond the preview
Go deeper on Qnovia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qnovia.